Category Archives: Cancer Research

Benefits Of Oncotarget To Researchers

Oncotarget began as an online platform where scientists could post and access latest papers or publications on oncology. It became very successful over time that the editors introduced new branches such as microbiology, neuroscience, aging, immunology, pathology, autophagy, and cell death. However, Oncotarget’s primary focus is still oncology.

The impact brought about by Oncotarget is quite fascinating. Unlike before, now researchers can share their work as soon as they complete them. They no longer have to wait for reviews to so as to make their work available to the rest of the world.

Read more: https://www.dovepress.com/oncotargets-and-therapy-journal

The editors on this online platform ensure the site is up and running always, enabling their target audience to post and access updates on a weekly basis. Researchers can also post unfinished works here and be able to read all the unbiased reviews made by other scientists. Most times, these researchers use the comments made to better their research and even complete and present their papers for publication.

Medicine students also benefit immensely from Oncotarget. They can find most, if not all, of the materials they require for their projects here. It, therefore, means that they do not have to spend a lot of time completing their work or even include outdated research in their projects since they have access to updated publications.

If you are a new researcher, you need not worry about rejection of your papers. Oncotarget is known to have a very high acceptance rate of work that is outstanding and of great impact. Just make sure your research is extensive and up to date.

According to this article, Oncotarget charges researchers a nominal fee for the publication, promotion or archiving of their work. The amount is negotiable. Hence, scientists are allowed to ask for a discount before submitting their papers. However, news or editorials of 800 words or less are free.

Oncotarget’s mission is to make scientific results widely and rapidly available to everyone across the globe. It links different scientific fields in medicine thus eliminating the border between specialties.

Oncotarget has already hastened the rate at which science is expanding, and humanity can have faith that most of the diseases we know right now will go extinct pretty soon. Follow Oncotarget journal on Twitter.

An Overview of Oncologist Mikhail Blagosklonny’s Life and Career

Mikhail Blagosklonny is a renowned author of more than 260 articles published in various peer-reviewed journals. These papers have received more than 25,000 citations, which has made him attain an h-index of 83. Dr. Blagosklonny is the current associate editor of Cancer Biology Therapy and Cell Death Differentiation. He has also served on the editorial board of Autophagy, Cancer Research, PLOS ONE, Intenational J Cancer and the founding and current Cell Cycle editor-in-chief. His areas of interest in research range from cellular and molecular biology to medical investigations that include cell cycle, signal transduction, anticancer therapeutics, cellular senescence and fresh anticancer strategies. He increased his studies on signal transduction from cancer to the area of aging On tandfonline.com. This revealed potential targets useful for slowing down age-related diseases and aging.

Education and Career

He started off his career as an associate professor of medicine after getting appointed at the New York Medical College, Valhalla in 2002. He then became a senior scientist at impactjournals.com at the Ordway Research Institute in Albany, New York. He held onto this position until 2009 when Blagosklonny was appointed as the Professor of Oncology, Roswell Park Cancer Institute.

Aging and the use of Rapamycin

Blagosklonny has come up with a hypothesis looking at the probable role of TOR signaling in cancer and aging. He proposes the use of rapamycin, which is a popular drug used for cancer as a potential treatment for extension of life. Rapamycin when administered in rational schedules and doses can prevent nephropathy, retinopathy and beta-cell failure without any side effects. Dr. Blagosklonny is known and considered as one of rapamycin’s passionate advocates in the longevity research.

Role at Roswell Park Cancer Institute

According to the Senior Vice-President at Roswell Park’s Basic Science and Chairman of Department of the Cell Stress Biology at https://www.linkedin.com/in/mikhail-blagosklonny-91abb531, Andrei V. Gudkov, Mikhail is a pre-eminent researcher. Andrei praised his unique concepts that he has developed in cancer therapy and biology at the time when Dr. Blagosklonny was recruited at Roswell Park (April 15, 2009). Dr. Blagosklonny has helped in facilitating the development of fresh anti-cancer methods and strategies and various cancer prevention and therapy methods. He has been able to achieve all the above due to his approaches and ideas that include protecting normal body cells from chemo- and radiotherapy, tissue-specific and anti-tissue therapy, anticancer drugs selective combination and the slowdown of cancer via slowing down the aging process in organisms.